These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7791505)

  • 1. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats.
    Sasaki H; Hashimoto K; Maeda Y; Inada T; Kitao Y; Fukui S; Iyo M
    Life Sci; 1995; 56(25):PL443-7. PubMed ID: 7791505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol.
    Sasaki H; Hashimoto K; Inada T; Fukui S; Iyo M
    Eur J Pharmacol; 1995 Aug; 282(1-3):71-6. PubMed ID: 7498291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram.
    Iyo M; Bi Y; Hashimoto K; Inada T; Fukui S
    Eur J Pharmacol; 1996 Sep; 312(2):163-70. PubMed ID: 8894591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo.
    Wachtel H
    J Pharm Pharmacol; 1983 Jul; 35(7):440-4. PubMed ID: 6136585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
    Casacchia M; Meco G; Castellana F; Bedini L; Cusimano G; Agnoli A
    Pharmacol Res Commun; 1983 Mar; 15(3):329-34. PubMed ID: 6304787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor.
    Barnard JW; Seibert AF; Prasad VR; Smart DA; Strada SJ; Taylor AE; Thompson WJ
    J Appl Physiol (1985); 1994 Aug; 77(2):774-81. PubMed ID: 8002527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
    Gordeladze JO
    Biosci Rep; 1990 Aug; 10(4):375-88. PubMed ID: 2174276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.
    Sato T; Otaka M; Odashima M; Kato S; Jin M; Konishi N; Matsuhashi T; Watanabe S
    Biochem Biophys Res Commun; 2006 Jul; 346(1):339-44. PubMed ID: 16759642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
    Souness JE; Hassall GA; Parrott DP
    Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
    Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
    Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice.
    Mori T; Baba J; Ichimaru Y; Suzuki T
    Jpn J Pharmacol; 2000 Jun; 83(2):113-8. PubMed ID: 10928323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram.
    Kochetkova M; Burns FM; Souness JE
    Biochem Pharmacol; 1995 Dec; 50(12):2033-8. PubMed ID: 8849330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
    Shafiee-Nick R; Pyne NJ; Furman BL
    Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
    Wachtel H
    Neuropharmacology; 1983 Mar; 22(3):267-72. PubMed ID: 6302550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
    Torphy TJ; Zhou HL; Cieslinski LB
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
    Kanes SJ; Tokarczyk J; Siegel SJ; Bilker W; Abel T; Kelly MP
    Neuroscience; 2007 Jan; 144(1):239-46. PubMed ID: 17081698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rolipram on in vivo dopamine receptor binding.
    Hosoi R; Ishikawa M; Kobayashi K; Gee A; Yamaguchi M; Inoue O
    J Neural Transm (Vienna); 2002 Sep; 109(9):1139-49. PubMed ID: 12203041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects induced by rolipram, a selective cAMP phosphodiesterase inhibitor: interaction with adrenergic and calcium affecting drugs.
    Novara V; Flugy A; Antona A; Latteri S; Palazzoadriano M; Cannizzaro G
    Pharmacol Res; 1990; 22 Suppl 1():51-2. PubMed ID: 2178260
    [No Abstract]   [Full Text] [Related]  

  • 20. The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration.
    Knapp CM; Foye MM; Ciraulo DA; Kornetsky C
    Pharmacol Biochem Behav; 1999 Jan; 62(1):151-8. PubMed ID: 9972858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.